MindWalk Holdings Corp. (NASDAQ: HYFT) has received board authorization for a share repurchase program that will allow the company to buy back up to 2.3 million common shares over the next 12 months. The program represents approximately 5% of the company's 46.15 million outstanding shares and is scheduled to begin on October 15, 2025.
Chief Executive Officer Jennifer Bath stated that the repurchase authorization demonstrates the company's confidence in MindWalk's long-term prospects and provides flexibility to acquire shares when market prices diverge from intrinsic value. The company plans to fund the share purchases through existing cash reserves, investments, or future cash flows generated from operations.
The announcement signals management's belief that the company's current market valuation may not fully reflect the potential of its bio-native artificial intelligence platform. MindWalk specializes in transforming drug discovery and development through its proprietary HYFT technology and LensAI platform. The company's approach unifies sequence, structure, function, and scientific literature into a single computational language while maintaining integration with full-stack laboratory operations.
MindWalk's technology platform supports multiple advanced applications in pharmaceutical development, including rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics. These capabilities enable the conversion of research insights into validated drug candidates at accelerated speeds compared to traditional methods. Additional information about the company's technology and operations is available at https://www.ipatherapeutics.com/.
The share repurchase program represents a significant financial commitment by the company and reflects executive confidence in both current operations and future growth prospects. By reducing the number of outstanding shares, the program could potentially increase earnings per share for remaining stockholders while demonstrating management's alignment with shareholder interests. The timing and exact amount of shares repurchased will depend on market conditions, regulatory requirements, and corporate considerations throughout the authorization period.
This corporate action follows standard practices for companies seeking to return value to shareholders while maintaining financial flexibility. The 12-month duration provides the company with ample opportunity to execute repurchases during favorable market conditions while continuing to invest in research and development initiatives. The program's structure allows MindWalk to balance capital allocation between strategic growth investments and shareholder returns.
